Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2016. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the fair market value of Ordinary Shares sold to meet tax liabilities, which was £13.9947 per share.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a specific transaction where Mrs. V Whyte sold 6,143 Ordinary Shares on February 29, 2016, to satisfy tax liabilities following the vesting of a 2013 Share Value Plan (SVP) award.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It strictly adheres to the Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of PDMR transactions.
Investor Verification Points
- Verify the share price of £13.9947 against market data for February 29, 2016.
- Confirm the total number of shares sold (6,143) by Mrs. V Whyte.
- Note that this filing does not contain quarterly or annual financial performance data.